atenolol has been researched along with Kidney Diseases in 22 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the antihypertensive, renal haemodynamic and antiproteinuric effect of enalapril and atenolol in patients with proteinuria of non-diabetic origin." | 9.07 | Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. ( Apperloo, AJ; de Jong, PE; de Zeeuw, D; Sluiter, HE, 1991) |
| "To compare the antihypertensive, renal haemodynamic and antiproteinuric effect of enalapril and atenolol in patients with proteinuria of non-diabetic origin." | 5.07 | Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. ( Apperloo, AJ; de Jong, PE; de Zeeuw, D; Sluiter, HE, 1991) |
| "Tertatolol is a new beta-blocker with specific vasodilatory properties, and thus might be particularly useful in CsA-treated transplant recipients." | 2.69 | Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A. ( Branten, AJ; Hilbrands, LB; Huysmans, FT; Koene, RA; van Hamersvelt, HW, 1998) |
| "Atenolol is a hydrophilic betareceptor blocking drug, which is predominantly eliminated via the kidneys, only about 5% of the atenolol is metabolised by the liver." | 2.36 | Clinical pharmacokinetics of atenolol--a review. ( Görg, KG; Kirch, W, 1982) |
| "Hypertension is present in nearly 80% of dialysis patients yet adequately controlled in less than half." | 1.34 | ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. ( Coyne, DW; Nath, V; Zheng, S, 2007) |
| " There was no significant difference in atenolol half-life when administered by the two routes." | 1.26 | Pharmacokinetics, pharmacology of atenolol and effect of renal disease. ( Koda, RT; Maronde, RF; Wan, SH, 1979) |
| " In patients with normal renal function the atenolol half-life was calculated to be about six hours following single 100 mg oral doses." | 1.26 | Pharmacokinetics of atenolol in patients with renal impairment. ( Legheand, J; McAinsh, J; Pozet, N; Sassard, J; Zech, P, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (31.82) | 18.7374 |
| 1990's | 5 (22.73) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 5 (22.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avdeef, A | 1 |
| Tam, KY | 1 |
| Chirinos, JA | 1 |
| Townsend, RR | 1 |
| Georgianos, PI | 1 |
| Agarwal, R | 1 |
| Szeto, CC | 1 |
| Li, PK | 1 |
| Igase, M | 1 |
| Yokoyama, H | 1 |
| Ferrario, CM | 1 |
| Dimopoulos-Xicki, L | 1 |
| Haas, M | 1 |
| Shord, SS | 1 |
| Thompson, DM | 1 |
| Krempl, GA | 1 |
| Hanigan, MH | 1 |
| Xie, HH | 1 |
| Shen, FM | 1 |
| Zhang, XF | 1 |
| Jiang, YY | 1 |
| Su, DF | 1 |
| Zheng, S | 1 |
| Nath, V | 1 |
| Coyne, DW | 1 |
| Kirch, W | 3 |
| Görg, KG | 1 |
| Schäfer, M | 2 |
| Braun, M | 1 |
| Köhler, H | 1 |
| Mutschler, E | 1 |
| van Essen, GG | 2 |
| Rensma, PL | 2 |
| de Zeeuw, D | 3 |
| Sluiter, WJ | 2 |
| Scheffer, H | 1 |
| Apperloo, AJ | 3 |
| de Jong, PE | 3 |
| Stegeman, CA | 1 |
| Branten, AJ | 1 |
| Hilbrands, LB | 1 |
| van Hamersvelt, HW | 1 |
| Koene, RA | 1 |
| Huysmans, FT | 1 |
| Wan, SH | 1 |
| Koda, RT | 1 |
| Maronde, RF | 1 |
| Decourt, S | 1 |
| Flouvat, B | 1 |
| Sassard, J | 1 |
| Pozet, N | 1 |
| McAinsh, J | 1 |
| Legheand, J | 1 |
| Zech, P | 1 |
| Melina, D | 1 |
| Guerrera, G | 1 |
| Santoliquido, A | 1 |
| Guerrera, C | 1 |
| Musumeci, V | 1 |
| Nicolò, G | 1 |
| Cataldo, R | 1 |
| Sluiter, HE | 1 |
| Giang, DW | 1 |
| Isaeff, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Genetic Predisposition of Chronic Nephrotoxicity From Calcineurin Inhibitors in Liver Transplant Recipients, Potential Correlation With Urinary Biomarkers[NCT00857844] | 207 participants (Actual) | Observational | 2007-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for atenolol and Kidney Diseases
| Article | Year |
|---|---|
Clinical pharmacokinetics of atenolol--a review.
Topics: Administration, Oral; Atenolol; Biological Availability; Drug Interactions; Humans; Injections, Intr | 1982 |
5 trials available for atenolol and Kidney Diseases
| Article | Year |
|---|---|
Effect of lisinopril and atenolol on aortic stiffness in patients on hemodialysis.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antih | 2015 |
Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Double-Blind Method | 1996 |
Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aten | 1997 |
Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Cross-Over Studies; Cyclosporine; Fema | 1998 |
Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease.
Topics: Adult; Atenolol; Blood Pressure; Double-Blind Method; Enalapril; Female; Hemodynamics; Humans; Kidne | 1991 |
16 other studies available for atenolol and Kidney Diseases
| Article | Year |
|---|---|
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological | 2010 |
Reducing arterial stiffness in CKD: revising the paradigms.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2015 |
Cardiovascular disease: Questioning the effect of β-blockers on vascular stiffness.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2015 |
Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7).
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Anim | 2011 |
[Therapeutic implications of ACE-gene polymorphism].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer.
Topics: Albuterol; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Atenolol; Cispla | 2006 |
Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs.
Topics: Animals; Antihypertensive Agents; Aorta; Atenolol; Baroreflex; Biphenyl Compounds; Blood Pressure; C | 2006 |
[Kidney protection leads to heart protection, too].
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive | 2006 |
ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2007 |
Single intravenous dose kinetics accumulation of atenolol in patients with impaired renal function and on hemodialysis.
Topics: Adult; Aged; Atenolol; Glomerular Filtration Rate; Half-Life; Humans; Injections, Intravenous; Kidne | 1980 |
Pharmacokinetics of atenolol in relation to renal function.
Topics: Administration, Oral; Adult; Aged; Atenolol; Female; Glomerular Filtration Rate; Humans; Injections, | 1981 |
Pharmacokinetics, pharmacology of atenolol and effect of renal disease.
Topics: Administration, Oral; Adult; Atenolol; Creatinine; Female; Half-Life; Humans; Injections, Intravenou | 1979 |
[Determination in biologic media of a new beta-blocker, atenolol, by high performance liquid chromatography].
Topics: Atenolol; Chromatography, High Pressure Liquid; Humans; Kidney Diseases; Propanolamines; Spectrometr | 1979 |
Pharmacokinetics of atenolol in patients with renal impairment.
Topics: Atenolol; Blood Pressure; Heart Rate; Humans; Hypertension; Kidney Diseases; Kinetics; Propanolamine | 1977 |
[Efficacy of the combination of nicardipine-enalapril and atenolol in severe hypertension secondary to chronic renal disease].
Topics: Adult; Atenolol; Chronic Disease; Drug Therapy, Combination; Enalapril; Female; Humans; Hypertension | 1992 |
Atenolol overdosage in a patient with progressive renal failure.
Topics: Atenolol; Bradycardia; Humans; Hypotension; Kidney Diseases; Male; Middle Aged | 1986 |